Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,237 total articles
McDonald's is more than burgers and advertising - its balance sheet and cash flow are anchored by a quasi-real-estate business. With a market cap near $201B, free cash flow of roughly $6.7B and a dividend yield around 2.7%, the stock looks set for a mid-term re-rating if management levers real estate optionality and the consumer stabilizes. This is…
Bicara (BCAX) is a clinical-stage oncology name with encouraging Phase 1b signals for its lead bifunctional antibody and a freshly replenished war chest after an oversubscribed offering. Technicals and short-interest create near-term noise, but the combination of strong response data, $172.5M+ of gross proceeds and a sub-$2B market cap make a long …
Intuit has been punished for a weak TurboTax cycle, a 17% workforce reduction announcement, and a flurry of class-action headlines. At roughly $96 billion market cap and a P/E near 19-20, the company still generates meaningful free cash flow ($7.76B) and retains solid profitability metrics (ROE ~22%, EV/EBITDA ~14.2). This trade idea proposes a mea…
Astrana Health (ASTH) is a physician-centric, risk-bearing healthcare platform that is profitable and generating free cash flow. With recent revenue acceleration, a manageable valuation on an EV/sales basis, and heavy short interest, the stock sets up as a high-conviction swing trade. This idea is a defined-risk long: entry $35.25, stop $30.50, pri…
Intuitive Surgical (ISRG) is a high-quality, cash-generative medtech franchise trading below prior multiples after a rocky product transition and tariff-driven margin pressure. The stock sits near $400 with a market cap around $151B, an installed base north of 11,700 da Vinci systems, and recurring parts & service revenue that drives predictable ca…
RTX's Q2 profile centers on a $289 billion backlog that provides multi-year revenue visibility and defense cashflow resilience. That strength supports a constructive long idea, but the stock's valuation and exposure to cyclical commercial aerospace demand mean the trade is best sized as a patient, pullback-driven long with a clearly defined stop.
Better Home & Finance (BETR) remains a story stock with real product wins — warehouse lines, Fannie/Coinbase programs — but recent misses, a CEO shakeup and large negative cash flow make this a binary setup. For nimble traders willing to take concentrated risk, a disciplined mid-term long with a tight stop offers asymmetric upside if management sta…
Jazz Pharmaceuticals' reported acquisition of Actio Biosciences gives the company immediate scale in epilepsy and complements its existing CNS portfolio. With a $250 stock pivoting off recent clinical wins in oncology and solid free cash flow, a tactical swing long over the next 45 trading days offers asymmetric upside if integration and commercial…
Diamondback Energy offers concentrated Permian exposure, robust free cash flow ($3.68B) and a conservative balance sheet (debt/equity 0.33). Valuation is mixed — a premium P/E (~38x) versus attractive EV/EBITDA (~6.1x) — making this a tactical long for investors who want oil upside with operational resilience. Trade plan: enter at $200.53, target $…
Kimberly-Clark (KMB) is facing near-term headwinds from elevated input costs and restructuring-related charges, but the combination of scale, a 4.7% yield, $1.82B in free cash flow and expected $2.1B in annual synergies from the Kenvue integration argues for a mid-term buy. Valuation is reasonable with a $36B market cap, EV/EBITDA ~13x and P/E near…
Banyan Gold (BYAGF) is showing bullish technicals, increasing short interest and a favorable moving-average structure that together create an asymmetric risk/reward for disciplined, patient traders. We lay out an actionable trade with entry at $1.28, a stop at $0.98 and a $2.20 target over a 180 trading day horizon.
Novo Nordisk's shares are trading well below historic highs after a string of negative headlines and competitive concerns. The company's core Diabetes & Obesity franchise still generates strong operating profits, supports a 2.6% dividend yield, and leaves room for upside if growth normalizes. This trade idea lays out a clear long entry, stop and ta…
U.S. GoldMining’s Whistler gold-copper project just cleared a major validation hurdle with a positive PEA and the company has mobilized a 2026 drill program intended to expand resources. The market cap sits near $138M while the PEA shows an after-tax NPV of $2.04B at base case prices, creating a large optionality gap. This trade idea recommends a l…
Venture Global has moved from speculative project developer to an operating LNG seller with commercialized capacity. The stock still trades as if the business is years away from cash generation — that disconnect creates a tradeable long with defined risk. Entry $12.50, target $20.00, stop $9.50; horizon: long term (180 trading days).
Flywire has been punished over visa and permit headlines, but the company’s growth, improving margins, and strong free cash flow argue that much of the pain is already priced in. At roughly $2.2B market cap and an EV/Sales near 2.6x, this is a tactical mid-term long for investors willing to tolerate headline volatility. Entry $17.30, stop $15.00, t…
Global Payments (GPN) is trading below recent highs despite solid cash generation, a large buyback and favorable industry fundamentals. The market is pricing significant execution risk; we think upside to the mid-high $90s is a realistic 45-trading-day outcome. Actionable long trade with clear entry, stop and target.
Nvidia's market position in GPUs and an emerging CPU opportunity already underpin a massive AI infrastructure story. If the reported near-$500 billion strategic transaction materializes, it would materially change growth expectations and hyperscaler dynamics. This trade idea lays out a long entry near the current price, a defined stop-loss, and a l…
Information Services Group (III) is a compact, profitable sourcing and technology advisory firm trading at roughly $5.12. The business generates meaningful free cash flow ($16.95M), carries modest leverage (debt/equity ~0.62), and pays a quarterly cash dividend. With EV of ~$285M and EV/EBITDA ~11.4, the stock looks reasonable for a 180-day trade t…
Fluent (FLNT) is trading at roughly $4.12 with a market cap near $145M and an enterprise value to sales of ~0.75x. The company is shifting toward higher-margin commerce media (up 121% in Q2 2025) while adding New York retail and cultivation via the RIV Capital deal. For traders, the set-up is a mid-term long: entry $4.12, stop $3.25, target $6.00 o…
SpaceX faces intense skepticism today, but the company's differentiated launch economics, Starlink revenue runway and Starship-enabled TAM expansion argue for a patient, defined-risk long. This trade idea lays out an entry at $85.00, a stop at $66.00 and a $140.00 target over a long-term (180 trading days) horizon.
Alphabet looks underpriced relative to the durability of its AI-driven revenue streams. With a market cap near $4.2 trillion, free cash flow of roughly $53.3B and a P/E around 17x, the stock offers an asymmetric risk/reward as hyperscaler demand for AI infrastructure remains structural. I recommend a long trade sized with a medium-risk allocation, …
CLEAR (YOU) has pulled back from recent highs into oversold territory while fundamentals - membership growth, revenue beats and rising free cash flow - remain intact. This trade idea proposes a disciplined buy-the-dip entry at $46.50 with a $60 target over a swing window as travel demand and identity-verification adoption continue to accelerate.
Dow (DOW) looks compelling after management’s cost actions and persistent demand in key chemical markets. The shares trade at roughly $30.75 with a market cap near $22.7B and free cash flow of $1.46B, supporting a 4.7% dividend and room for multiple expansion. We upgrade to a tactical long and recommend entering at $30.75, targeting $37.00 over the…
Rocket Lab (RKLB) is priced for growth more than profits. With record top-line momentum (Q2 revenue of $234M, ~62% YoY) and a $2.36B backlog, the company’s upcoming Neutron program milestones set the stage for margin expansion and, potentially, sustained profitability. This trade idea lays out a long entry around current levels with a clear stop an…
Legend Biotech's recent in vivo CAR-T readout and manufacturing expansion make its pipeline narrative real. Pair that with improving technicals and manageable financing, and there is a mid-term trade worth considering: enter on weakness, target the $30 area, and protect capital with a below-$18 stop.
